Alk1:BMPRII agonism via bispecific clustering antibody for the treatment of HHT & PАН

Presented at Genetics-inspired Therapeutics for PH by Patrick Andre, Diagonal Therapeutics

Summary

This presentation explores a novel bispecific clustering antibody approach for treating Hereditary Hemorrhagic Telangiectasia (HHT) and Pulmonary Arterial Hypertension (PAH).  The therapy targets ALK1 and BMPR2 signaling pathways, crucial for vascular health.  Research demonstrates the antibody's efficacy in preclinical models, correcting defective signaling and preventing disease pathology.  Clinical trials are imminent, offering hope for patients with these rare vascular disorders.

Generated by AI, edited by PVRI